Exelixis EXEL R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's R&D?
- Exelixis (EXEL) reported R&D of $199.92M in Q1 2026.
- How has Exelixis's R&D changed year-over-year?
- Exelixis's R&D decreased by 5.8% year-over-year, from $212.23M to $199.92M.
- What is the long-term trend for Exelixis's R&D?
- Over 4 years (2021 to 2025), Exelixis's R&D has grown at a 4.4% compound annual growth rate (CAGR), from $693.72M to $825M.
- What does R&D mean?
- Spending on the discovery and clinical testing of new medical treatments.
- How do you interpret R&D?
- Higher spending indicates a commitment to pipeline expansion, though it may temporarily depress current profitability.
- How does R&D compare across companies?
- A critical benchmark for all biotech firms; peers vary based on clinical trial stages.